NZ759513A - Human antibodies to bet v 1 and methods of use thereof - Google Patents

Human antibodies to bet v 1 and methods of use thereof

Info

Publication number
NZ759513A
NZ759513A NZ759513A NZ75951318A NZ759513A NZ 759513 A NZ759513 A NZ 759513A NZ 759513 A NZ759513 A NZ 759513A NZ 75951318 A NZ75951318 A NZ 75951318A NZ 759513 A NZ759513 A NZ 759513A
Authority
NZ
New Zealand
Prior art keywords
antibodies
bet
seq
fagales
allergens
Prior art date
Application number
NZ759513A
Other languages
English (en)
Inventor
Andrew J Murphy
Yashu Liu
Jamie M Orengo
Ashok T Badithe
Vishal Kamat
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Priority to NZ782911A priority Critical patent/NZ782911B2/en
Publication of NZ759513A publication Critical patent/NZ759513A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NZ759513A 2017-06-01 2018-05-31 Human antibodies to bet v 1 and methods of use thereof NZ759513A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ782911A NZ782911B2 (en) 2018-05-31 Human antibodies to bet v 1 and methods of use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762513872P 2017-06-01 2017-06-01
US201762571696P 2017-10-12 2017-10-12
US201862662165P 2018-04-24 2018-04-24
PCT/US2018/035366 WO2018222854A1 (en) 2017-06-01 2018-05-31 Human antibodies to bet v 1 and methods of use thereof

Publications (1)

Publication Number Publication Date
NZ759513A true NZ759513A (en) 2022-01-28

Family

ID=62705709

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ759513A NZ759513A (en) 2017-06-01 2018-05-31 Human antibodies to bet v 1 and methods of use thereof

Country Status (17)

Country Link
US (3) US10793624B2 (https=)
EP (1) EP3630814A1 (https=)
JP (3) JP6963036B2 (https=)
KR (3) KR102329175B1 (https=)
CN (1) CN110997713B (https=)
AU (2) AU2018275657B2 (https=)
BR (1) BR112019025150B1 (https=)
CA (1) CA3063588A1 (https=)
CL (3) CL2019003508A1 (https=)
CO (1) CO2019013196A2 (https=)
IL (2) IL270894B2 (https=)
MX (2) MX2019014430A (https=)
MY (1) MY198270A (https=)
NZ (1) NZ759513A (https=)
PH (1) PH12019550238A1 (https=)
WO (1) WO2018222854A1 (https=)
ZA (1) ZA201907513B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107635527B (zh) 2015-03-10 2021-04-23 里珍纳龙药品有限公司 无菌刺穿系统和方法
IL308643B2 (en) 2017-05-05 2025-02-01 Regeneron Pharma Auto-injector
IL270894B2 (en) * 2017-06-01 2023-04-01 Regeneron Pharma Human antibodies to bet v 1 and methods of using them
AU2021300129A1 (en) 2020-07-01 2022-12-08 Regeneron Pharmaceuticals, Inc. Methods of treating allergy using anti-Bet v 1 antibodies
CN113041271B (zh) * 2021-04-14 2022-12-27 浙江养生堂天然药物研究所有限公司 具有预防和抗过敏功效的组合物
USD1007676S1 (en) 2021-11-16 2023-12-12 Regeneron Pharmaceuticals, Inc. Wearable autoinjector
US20230174632A1 (en) * 2021-12-08 2023-06-08 IgGenix, Inc. Combinations for allergy therapy
EP4688165A1 (en) 2023-03-31 2026-02-11 ALK-Abelló A/S Allergen binding antibodies suitable for treating tree pollen allergies
WO2024251358A1 (en) * 2023-06-07 2024-12-12 Mabylon Ag Anti-allergen antibodies and uses thereof
CN121548440A (zh) 2023-06-16 2026-02-17 里珍纳龙药品有限公司 医疗装置包装及相关方法
US20250011403A1 (en) * 2023-07-03 2025-01-09 Medicovestor, Inc. Nucleic acids, vectors, and cells that encode anti-sp17 antibodies and other sp17 binding proteins
US12319747B2 (en) 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
WO2025075970A1 (en) 2023-10-02 2025-04-10 Regeneron Pharmaceuticals, Inc. Drug delivery device safety system
US12364777B2 (en) 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
WO2025117894A2 (en) * 2023-11-29 2025-06-05 Medicovestor, Inc. Dimeric immunoconjugates for use in treating cancers and methods of use
US12116410B1 (en) 2023-12-26 2024-10-15 Medicovestor, Inc. Methods of manufacturing dimeric antibodies
US12600795B2 (en) 2023-12-26 2026-04-14 Medicovestor, Inc. Oligomeric IgG for immunotherapeutics and diagnostics
US20250263471A1 (en) 2024-01-30 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of treating allergy using anti-bet v 1 antibodies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5411594A (en) 1992-10-27 1994-05-24 Biomay Produktions- Und Handelsgesellschaft M.B.H. Molecule fragments (peptides) of the main allergens contained in the pollen of trees of the (fagales) order
WO1994014475A1 (en) 1992-12-21 1994-07-07 Tanox Biosystems, Inc. ALLERGEN-SPECIFIC IgA MONOCLONAL ANTIBODIES AND RELATED PRODUCTS FOR ALLERGY TREATMENT
EP0619323A1 (en) * 1993-04-09 1994-10-12 Schering-Plough Human monoclonal antibodies and processes and materials for making such antibodies
GB0002386D0 (en) 2000-02-02 2000-03-22 Novartis Nutrition Ag Therapeutic composition
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
ITMI20052517A1 (it) * 2005-12-29 2007-06-30 Lofarma Spa Varianbtio ipoallergeniche dell'allergene maggiore bet v 1 di polline di betula verrucosa
AT503297B1 (de) * 2006-05-18 2007-09-15 Biomay Ag Allergen-spezifische antikörper
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
GB201002559D0 (en) 2010-02-15 2010-03-31 Circassia Ltd Birch peptides for vaccine
TW201920262A (zh) * 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
US10935554B2 (en) * 2013-08-23 2021-03-02 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT)
IL270894B2 (en) 2017-06-01 2023-04-01 Regeneron Pharma Human antibodies to bet v 1 and methods of using them
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
AU2021300129A1 (en) * 2020-07-01 2022-12-08 Regeneron Pharmaceuticals, Inc. Methods of treating allergy using anti-Bet v 1 antibodies

Also Published As

Publication number Publication date
CO2019013196A2 (es) 2020-01-17
KR102878718B1 (ko) 2025-10-31
JP6963036B2 (ja) 2021-11-05
JP2020523004A (ja) 2020-08-06
KR20200012892A (ko) 2020-02-05
ZA201907513B (en) 2022-04-28
JP2021112207A (ja) 2021-08-05
AU2022200272A1 (en) 2022-02-10
CN110997713A (zh) 2020-04-10
CA3063588A1 (en) 2018-12-06
AU2022200272B2 (en) 2024-10-03
KR102674000B1 (ko) 2024-06-11
IL298034B2 (en) 2024-05-01
CL2021002851A1 (es) 2022-08-19
AU2018275657A1 (en) 2019-12-19
KR20210143327A (ko) 2021-11-26
CL2019003508A1 (es) 2020-06-19
IL270894A (en) 2020-01-30
MX2023000390A (es) 2023-02-13
CL2021002850A1 (es) 2022-06-24
US11767358B2 (en) 2023-09-26
NZ782911A (en) 2025-08-29
JP7162097B2 (ja) 2022-10-27
US20210054056A1 (en) 2021-02-25
KR20240096746A (ko) 2024-06-26
JP7458453B2 (ja) 2024-03-29
BR112019025150A2 (pt) 2020-06-23
CN110997713B (zh) 2024-01-02
JP2022174238A (ja) 2022-11-22
KR102329175B1 (ko) 2021-11-19
IL270894B2 (en) 2023-04-01
MX2019014430A (es) 2020-07-14
US20180346555A1 (en) 2018-12-06
PH12019550238A1 (en) 2020-10-19
EP3630814A1 (en) 2020-04-08
BR112019025150B1 (pt) 2022-11-08
IL298034B1 (en) 2024-01-01
WO2018222854A1 (en) 2018-12-06
IL270894B (en) 2022-12-01
MY198270A (en) 2023-08-18
US20240083986A1 (en) 2024-03-14
US10793624B2 (en) 2020-10-06
IL298034A (en) 2023-01-01
AU2018275657B2 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
NZ759513A (en) Human antibodies to bet v 1 and methods of use thereof
ZA202202846B (en) Human antibodies to fel d1 and methods of use thereof
TW200801041A (en) Antibodies against human IL-22 and uses therefor
WO2017075432A3 (en) Anti-siglec-9 antibodies and methods of use thereof
MY171180A (en) Anti-hla-b*27 antibodies and uses thereof
WO2014114651A9 (en) Tnf-alpha antigen-binding proteins
WO2007100643A3 (en) Methods of using antibodies against human il-22
WO2015066379A3 (en) Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide
WO2013173761A3 (en) St2 antigen binding proteins
NZ708033A (en) Anti-blood dendritic cell antigen 2 antibodies and uses thereof
WO2013192596A3 (en) Antigen binding proteins that bind ccr2
MY171226A (en) Antibodies that bind il-23
HK1199038A1 (en) Anti-human xcr1 antibodies
WO2014165028A8 (en) Antibodies specific to a novel epitope on cemx of human membrane-bound ige and uses thereof in treating ige-mediated diseases
WO2013122544A3 (en) IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES
WO2014043220A3 (en) Hiv-1 envelope proteins and fragments thereof that possess epitopes recognized by broadly neutralizing antibodies
PH12021550322A1 (en) Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof
WO2024027764A3 (en) Chimeric antigen receptor systems, methods of preparation, and uses thereof
WO2015077442A3 (en) Grass pollen immunogens and methods and uses thereof for immune response modulation
EA201992651A1 (ru) АНТИТЕЛА ЧЕЛОВЕКА К Bet v 1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA201491957A1 (ru) Антитела к ccl2 для лечения склеродермии
WO2013104901A3 (en) Novel therapies
WO2015077434A3 (en) Pan pollen immunogens and methods and uses thereof for immune response modulation
HK1227898A1 (en) Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide
TH1801000535A (th) โครงสร้างแอนติบอดีที่มีความจำเพาะแบบคู่ที่จับdll3และcd3

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 MAY 2024 BY ANAQUA SERVICES

Effective date: 20230420

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 MAY 2025 BY ANAQUA SERVICES

Effective date: 20240418

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 MAY 2026 BY ANAQUA SERVICES

Effective date: 20250423